Advertisement

Long-Term Multilineage Development from Human Umbilical Cord Blood Stem Cells in a Novel SCID-HU Graft

  • Christopher C. Fraser
  • Hideto Kaneshima
  • Gun Hansteen
  • Madison Kilpatrick
  • Ronald Hoffman
  • Benjamin P. Chen

Abstract

Although human hematopoietic stem cells can be isolated based on cell surface antigen expression, their proliferative and developmental capacity must still be defined by their ability to produce multiple hematopoietic cell lineages for prolonged times in vivo. In order to derive a long-term in vivo multilineage SCID-hu graft we transplanted a human fetal bone and spleen adjacent to an HLA class I mismatched fetal thymus fragment in immunodeficient SCID mice (SCID-hu BTS). Grafts were analyzed at various times post transplant for cells expressing specific lineage markers. The bone marrow of SCID-hu BTS grafts maintained B cells and myeloid cells for at least 36 weeks post transplant. Analysis for progenitor content within grafts revealed that CD34+ cells, CFU-G/M, and CFU-GEMM were maintained in 94%(109/116), 100%(66/66) and 79%(52/66) up to 28 weeks. HSC (CD34hiThy-l+Lin-) sorted from 20 week old SCID-hu BTS grafts demonstrated potent secondary multilineage reconstituting potential when injected into HLA mismatched SCID-hu bone grafts. In addition both immature and mature T-cells, derived from progenitors within the fetal bone, were found in 87%(101/116) of grafts analyzed up to 36 weeks in vivo. Injection of irradiated SCID-hu BTS grafts with CD34+Thy-1+Lin-umbilical cord blood cells produced B-cells, myeloid cells, T-cells and CD34+ cells in individual grafts when analyzed 8 weeks post reconstitution, further demonstrating the multipotential nature of these HSC populations. This model is currently being used to define soluble factors or cells that are capable of enhancing human HSC engraftment.

Keywords

Myeloid Cell Umbilical Cord Blood SCID Mouse Post Transplant Double Positive 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    . McCune JM, Namikawa R, KaneshimaH, Shultz LD, Lieberman M, Weissman IL. The SCID-hu mouse: Murine model for the analysis of human hematolymphoid differentiation and function. Science 241: 1632, 1988PubMedCrossRefGoogle Scholar
  2. 2.
    . Namikawa R, Weilbaecher KN, Kaneshima H, Yee EJ, McCune JM. Long-term hematopoiesis in the SCID-hu mouse. J Exp Med 172: 1055, 1990PubMedCrossRefGoogle Scholar
  3. 3.
    . Kaneshima H, Namikawa R, McCune JM. Human hematolymphoid cells in SCID mice. Curr Opp Immunol 6: 327, 1994CrossRefGoogle Scholar
  4. 4.
    . Vandekerckhove BAE, Jones D, Punnonen J, Schols D, Lin HC, Duncan B, Bacchetta R, de Vries JE, Roncarolo MG. Human Ig production and isotype switching on severe combined immunodeficient-human mice. J Immunol 151: 128, 1993PubMedGoogle Scholar
  5. 5.
    . Kyoizumi S, Baum CM, Kaneshima H, McCune JM, Yee E J, Namikawa R. Implantation and maintenance of functional human bone marrow within SCID-hu mice. Blood 79: 1704, 1992PubMedGoogle Scholar
  6. 6.
    . Adkins B, Mueller C, Okada CY, Reichert RA, Weissman IL, Spangrude GS. Early events in T-cell maturation. Ann Rev Immunol 5: 325, 1987CrossRefGoogle Scholar
  7. 7.
    . Tsukamoto A, Weissman I, Chen B, DiGiusto D, Baum C, Hoffman R, Uchida N: Phenotypic and functional analysis of hematopoietic stem cells in mouse and man, in Levitt D, Mertelsmann R (eds): Hematopoietic stem cells: biology and therapeutic applications.New York, Marcel Dekker Ine, 1994, p85Google Scholar
  8. 8.
    . Chen BP, Galy A, Kyoizumi S, Namikawa R, Scarborough J, Webb S, Ford B, Cen DZ, Chen S. Engraftment of human hematopoietic precursor cells with secondary transfer potential in SCID-hu mice. Blood 84: 2497, 1994PubMedGoogle Scholar
  9. 9.
    . DiGiusto D, Chen S, Combs J, Webb S, Namikawa R, Tsukamoto A, Chen BP, Galy AHM. Human fetal bone marrow progenitors for T, B and myeloid cells are found exclusively in the population expressing high levels of CD34. Blood 84: 421, 1994PubMedGoogle Scholar
  10. 10.
    . Baum CM, Weissman IL, Tsukamoto A, Buckle AM, Peault B. Isolation of a candidate human hematopoie¬tic stem-cell population. Proc Natl Acad Sci USA 89: 2804, 1992PubMedCrossRefGoogle Scholar
  11. 11.
    . Craig W, Kay R, Cutler RL, Lansdorp PM. Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 177: 1331, 1993PubMedCrossRefGoogle Scholar
  12. 12.
    . Lu L, Xiao M, Shen RN, Grisby S, Broxmeyer HE. Enrichment, characterization and responsiveness of single primitive CD34+ human umbilical cord blood hematopoietic progenitors with high proliferative and replating potential. Blood 81: 41, 1993PubMedGoogle Scholar
  13. 13.
    . Carow CE, Hangoc G, Broxmeyer HE. Human multipotential progenitor cells (CFU- GEMM) have extensive replating capacity for secondary CFU-GEMM: an effect enhanced by cord blood plasma. Blood 81: 942, 1993PubMedGoogle Scholar
  14. 14.
    . Mayani H, Lansdorp PM. Thy-1 expression is linked to functional properties of primitive hematopoietic progenitor cells from human umbilical cord blood. Blood 83: 2410, 1994PubMedGoogle Scholar
  15. 15.
    . Wagner JE, Broxmeyer HE, Byrd RL, Zehnbauer B, Schmeckpeper B, Shah N, Griffin C, Emanuel PD, Zuckerman KS, Cooper S, Carow C, Bias W, Santos GW. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood 79: 1874, 1992PubMedGoogle Scholar
  16. 16.
    . Browning MJ, Krausa P, Rowan P, Bicknell DC, Bodmer JG, Bodmer WF. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: Comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc Natl Acad Sci USA 90: 2842, 1993PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New york 1996

Authors and Affiliations

  • Christopher C. Fraser
    • 1
  • Hideto Kaneshima
    • 1
  • Gun Hansteen
    • 1
  • Madison Kilpatrick
    • 1
  • Ronald Hoffman
    • 1
  • Benjamin P. Chen
    • 1
  1. 1.Experimental Cell Therapy GroupSyStemix Inc.Palo AltoUSA

Personalised recommendations